Tianda Pharmaceuticals Limited (00455.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.6x

Market Cap

HKD 219.27M

MomentumView details →

1D Return

+0.99%

YTD Return

−20.93%

RSI (14)

43.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.6x

Market Cap

HKD 219.27M

RSI (14)

43.3

MomentumView details →

1D Return

+0.99%

YTD Return

−20.93%

ProfitabilityView details →

Gross Margin

44.19%

Net Margin

−15.86%

EBITDA Margin

−5.85%

ROE (TTM)

−25.88%

ROA (TTM)

−15.80%

Asset Turnover

0.98x

GrowthView details →

Revenue YoY

−33.71%

EPS YoY

−95.37%

FCF YoY

+105.82%

Revenue CAGR 3Y

−16.09%

EPS CAGR 3Y

−14.39%

EBITDA YoY

−87.55%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

0.83x

Quick Ratio

0.64x

Div Yield

—

Div Rate

—

Div Growth 1Y

+100.00%

Financials snapshotView financials →

Revenue (TTM)

744.85M

Net Income (TTM)

−118.16M

Op. CF (TTM)

—

Latest newsMore news →

Tianda Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of HK$164 million, up 20.2% year-on-year, net loss narrowed to HK$32.25 million, loss per share of HK$0.015, and no dividend.25d ago

Similar companies

Organogenesis Holdings Inc.ORGO Journey Medical CorporationDERM SIGA Technologies, Inc.SIGA Aurora Cannabis Inc.ACB Extrawell Pharmaceutical Holdings Limited00858.HK Cardiol Therapeutics Inc.CRDL Find similar companies →

Latest newsMore news →

Tianda Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of HK$164 million, up 20.2% year-on-year, net loss narrowed to HK$32.25 million, loss per share of HK$0.015, and no dividend.25d ago